BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel 1.5 mg
Phase 1
Completed
- Conditions
- Contraceptives, Postcoital
- Interventions
- Drug: Postinor 2Drug: Levonorgestrel Emergency Pill (BAY86-5028)
- First Posted Date
- 2010-02-23
- Last Posted Date
- 2014-04-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 32
- Registration Number
- NCT01073904
Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules
Phase 1
Completed
- Conditions
- Anti-Infective Agents
- Interventions
- First Posted Date
- 2010-02-23
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 26
- Registration Number
- NCT01073553
To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Ciprofloxacin (Cipro InhaIe, BAYQ3939)Drug: Placebo
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT01072942
Pharmacokinetic Study Comparing Aspirin and Aspirin Granules
Phase 1
Completed
- Conditions
- Pharmacokinetics
- Interventions
- Drug: Acetylsalicylic acid (Aspirin, BAY1019036)Drug: Acetylsalicylic acid (Aspirin, BAYE4465)
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 30
- Registration Number
- NCT01072604
FOCUS (Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry)
Phase 4
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 365
- Registration Number
- NCT01071122
QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea
Withdrawn
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- Bayer
- Registration Number
- NCT01071694
Survey to Assess Why People Are Not Responding to Treatment in Hypertension
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1589
- Registration Number
- NCT01071681
BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease
Phase 2
Completed
- Conditions
- Breast CancerBone Metastases
- Interventions
- First Posted Date
- 2010-02-18
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 23
- Registration Number
- NCT01070485
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
Phase 1
Completed
- Conditions
- Carcinoma, Non-Small-Cell LungLung Cancer
- Interventions
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 33
- Registration Number
- NCT01069328
Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection
Phase 3
Completed
- Conditions
- Intraabdominal Infections
- Interventions
- Drug: Moxifloxacin (Avelox, BAY12-8039)Drug: ErtapenemDrug: Ertapenem placeboDrug: Amoxicillin/ClavulanateDrug: Moxifloxacin placeboDrug: Amoxicillin/Clavulanate placebo
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 458
- Registration Number
- NCT01069900
- Locations
- 🇦🇷
Hospital de Agudos "Dr. Carlos Bocalandro", Tres De Febrero, Buenos Aires, Argentina
© Copyright 2025. All Rights Reserved by MedPath